Abstract:Background: Despite being one of the most common cancers, bladder cancer is largely inefficiently and inaccurately staged and monitored. Current imaging methods detect cancer only when it has reached "visible" size and has significantly disrupted the structure of the organ. By that time, thousands of cells will have proliferated and perhaps metastasized. Repeated biopsies and scans are necessary to determine the effect of therapy on cancer growth. In this report, we describe a novel approach based on multimodal nanoparticle contrast agent technology and its application to a preclinical animal model of bladder cancer. The innovation relies on the engineering core of mesoporous silica with specific scanning contrast properties and surface modification that include fluorescence and magnetic resonance imaging (MRI) contrast. The overall dimensions of the nano-device are preset at 80-180 nm, depending on composition with a pore size of 2 nm. Methods: To facilitate and expedite discoveries, we combined a well-known model of bladder cancer and our novel technology. We exposed nanoparticles to MB49 murine bladder cancer cells in vitro and found that 70 % of the cells were labeled by nanoparticles as measured by flow cytometry. The in vivo mouse model for bladder cancer is particularly well suited for T1- and T2-weighted MRI. Results: Under our experimental conditions, we demonstrate that the nanoparticles considerably improve tumor definition in terms of volumetric, intensity and structural characteristics. Important bladder tumor parameters can be ascertained, non-invasively, repetitively, and with great accuracy. Furthermore, since the particles are not biodegradable, repetitive injection is not required. This feature allows follow-up diagnostic evaluations during cancer treatment. Changes in MRI signals show that in situ uptake of free particles has predilection to tumor cells relative to normal bladder epithelium. The particle distribution within the tumors was corroborated by fluorescent microscopy of sections of excised bladders. In addition, MRI imaging revealed fibrous finger-like projections into the tumors where particles insinuated themselves deeply. This morphological characteristic was confirmed by fluorescence microscopy. Conclusions: These findings may present new options for therapeutic intervention. Ultimately, the combination of real-time and repeated MRI evaluation of the tumors enhanced by nanoparticle contrast may have the potential for translation into human clinical studies for tumor staging, therapeutic monitoring, and drug delivery.

Surface ligand-regulated renal clearance of MRI/SPECT dual-modality nanoprobes for tumor imaging

Ultra-Small and Metabolizable Near-Infrared Au/Gd Nanoclusters for Targeted FL/MRI Imaging and Cancer Theranostics

High‐Efficient Clearable Nanoparticles for Multi‐Modal Imaging and Image‐Guided Cancer Therapy

Excretable Lanthanide Nanoparticle For Biomedical Imaging And Surgical Navigation In The Second Near-Infrared Window

Recent Advances in Renal Clearable Inorganic Nanoparticles for Cancer Diagnosis

Renal Clearable Inorganic Nanoparticles: A New Frontier of Bionanotechnology

Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice.

Simultaneous multimodal imaging and photothermal therapy via renal-clearable manganese-doped copper sulfide nanodots

Renal clearance of quantum dots

Rapid Degradation and High Renal Clearance of Cu3BiS3 Nanodots for Efficient Cancer Diagnosis and Photothermal Therapy in Vivo

A Highly Active (102) Surface-Induced Rapid Degradation Of A Cus Nanotheranostic Platform For In Situ T-1-Weighted Magnetic Resonance Imaging-Guided Synergistic Therapy

99mTc-conjugated manganese-based mesoporous silica nanoparticles for SPECT, pH-responsive MRI and anti-cancer drug delivery.

Renal-clearable Nanoprobes for Optical Imaging and Early Diagnosis of Diseases

Renal Clearable Noble Metal Nanoparticles: Photoluminescence, Elimination, and Biomedical Applications.

Integrin Αvβ3 Receptor Overexpressing on Tumor-Targeted Positive MRI Guided Chemotherapy.

Pharmacokinetic Issues of Imaging with Nanoparticles: Focusing on Carbon Nanotubes and Quantum Dots

Detection of Kidney Dysfunction through In Vivo Magnetic Resonance Imaging with Renal-Clearable Gadolinium Nanoprobes

Rattle-Structured Multifunctional Nanotheranostics for Synergetic Chemo-/Radiotherapy and Simultaneous Magnetic/Luminescent Dual-Mode Imaging

Renal clearance and degradation of glutathione-coated copper nanoparticles.

Passive Tumor Targeting of Renal-Clearable Luminescent Gold Nanoparticles: Long Tumor Retention and Fast Normal Tissue Clearance.

Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles